Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

Kyra J. Fuchs, Marian van de Meent, M. Willy Honders, Indu Khatri, Michel G. D. Kester, Eva A. S. Koster, Georgia Koutsoumpli, Arnoud H. de Ru, Cornelis A. M. van Bergen, Peter A. van Veelen, Peter A. C. ’t Hoen, Peter van Balen, Erik B. van den Akker, J. Hendrik Veelken, Constantijn J. M. Halkes, J. H. Frederik Falkenburg, Marieke Griffioen

Blood (2024) 143 (18): 1856–1872.

https://doi.org/10.1182/blood.2023022343

Published: 2024

Includes: Supplemental data

Journal Articles

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Dennis F.G. Remst, Michel G.D. Kester, Dirk M. van der Steen, Arnoud H. de Ru, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 10292–10293.

https://doi.org/10.1182/blood-2022-170314

Published: 2022

Journal Articles

Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia

Georgia Koutsoumpli, Dyantha I. van der Lee, Nina C. Groenland, M. Willy Honders, Rob C.M. de Jong, Renate S. Hagedoorn, Hendrik Veelken, Peter A. van Veelen, Dominik Lock, Mirjam H.M. Heemskerk, J.H.Frederik Falkenburg, Ian Johnston, Marieke Griffioen

Blood (2022) 140 (Supplement 1): 10243–10244.

https://doi.org/10.1182/blood-2022-158195

Published: 2022

Journal Articles

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Miranda H. Meeuwsen, Anne K. Wouters, Tassilo L.A. Wachsmann, Renate S. Hagedoorn, Michel G.D. Kester, Dennis F.G. Remst, Dirk M. van der Steen, Arnoud H. de Ru, Els P. van Hees, Marieke Griffioen, Peter A. van Veelen, J.H. Frederik Falkenburg, Mirjam H.M. Heemskerk

Blood (2022) 140 (Supplement 1): 4498–4499.

https://doi.org/10.1182/blood-2022-156923

Published: 2022

Journal Articles

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

Nadine E. Struckman, Sebastian Klobuch, Michel G.D. Kester, Wendy de Klerk, Arnoud H. de Ru, Mirjam H.M. Heemskerk, Peter A. van Veelen, Peter van Balen, J.H.Frederik Falkenburg, Marieke Griffioen

Blood (2022) 140 (Supplement 1): 4545–4546.

https://doi.org/10.1182/blood-2022-166282

Published: 2022

Journal Articles

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

Thuja Meurer, Pietro Crivello, Maximilian Metzing, Michel Kester, Dominik A. Megger, Weiqiang Chen, Peter A. van Veelen, Peter van Balen, Astrid M. Westendorf, Georg Homa, Sophia E. Layer, Amin T. Turki, Marieke Griffioen, Peter A. Horn, Barbara Sitek, Dietrich W. Beelen, J. H. Frederik Falkenburg, Esteban Arrieta-Bolaños, Katharina Fleischhauer

Blood (2021) 137 (7): 923–928.

https://doi.org/10.1182/blood.2020008464

Published: 2021

Includes: Supplemental data

Journal Articles

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

Dyantha I. Van Der Lee, BSc., Helena M. Bijen, MSc, Renate S. Hagedoorn, ing., Willy M. Honders, ing., Michel G.D. Kester, ing., Dirk M. van der Steen, ing., Arnoud H. de Ru, ing., Inge Jedema, PhD, Hendrik Veelken, MD PhD, Mirjam H.M. Heemskerk, PhD, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Marieke Griffioen, PhD

Blood (2017) 130 (Supplement 1): 168.

https://doi.org/10.1182/blood.V130.Suppl_1.168.168

Published: 2017

Journal Articles

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

Lorenz Jahn, Pleun Hombrink, Renate S. Hagedoorn, Michel G. D. Kester, Dirk M. van der Steen, Tania Rodriguez, Tsvetelina Pentcheva-Hoang, Arnoud H. de Ru, Marjolein P. Schoonakker, Miranda H. Meeuwsen, Marieke Griffioen, Peter A. van Veelen, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk

Blood (2017) 129 (10): 1284–1295.

https://doi.org/10.1182/blood-2016-09-737536

Published: 2017

Includes: Supplemental data

Journal Articles

Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells

Cornelis A.M. van Bergen, PhD, Dirk M. van der Steen, Michel G.D. Kester, Marvyn T. Koning, BSc, Peter A. van Veelen, PhD, Marieke Griffioen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD, Hendrik Veelken, MD PhD, Marcelo A Navarrete, MD PhD

Blood (2016) 128 (22): 914.

https://doi.org/10.1182/blood.V128.22.914.914

Published: 2016

Journal Articles

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

Lorenz Jahn, Renate S. Hagedoorn, Pleun Hombrink, PhD, Michel G.D. Kester, Dirk M. van der Steen, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2015) 126 (23): 3002.

https://doi.org/10.1182/blood.V126.23.3002.3002

Published: 2015

Journal Articles

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

Mir Farshid Alemdehy, Jurgen R. Haanstra, Hans W. J. de Looper, Paulina M. H. van Strien, Judith Verhagen-Oldenampsen, Yvette Caljouw, Mathijs A. Sanders, Remco Hoogenboezem, Arnoud H. de Ru, George M. C. Janssen, Stephanie E. Smetsers, Marc B. Bierings, Peter A. van Veelen, Marieke von Lindern, Ivo P. Touw, Stefan J. Erkeland

Blood (2015) 125 (25): 3937–3948.

https://doi.org/10.1182/blood-2014-11-612507

Published: 2015

Includes: Supplemental data

Journal Articles

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G. D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2015) 125 (6): 949–958.

https://doi.org/10.1182/blood-2014-07-587840

Published: 2015

Includes: Supplemental data

Journal Articles

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

Lorenz Jahn, Pleun Hombrink, Michel G.D. Kester, Dirk M. van der Steen, Renate S. Hagedoorn, Chopie Hassan, Marjolein P. Schoonakker, Erwin van der Pijl, Peter A. van Veelen, PhD, J.H. Frederik Falkenburg, MD PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3832.

https://doi.org/10.1182/blood.V124.21.3832.3832

Published: 2014

Journal Articles

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

Lorenz Jahn, Pleun Hombrink, Chopie Hassan, Michel G.D. Kester, Renate S. Hagedoorn, Dirk M. van der Steen, Marjolein P. Schoonakker, J.H. Frederik Falkenburg, MD PhD, Peter A. van Veelen, PhD, Mirjam H.M. Heemskerk, PhD

Blood (2014) 124 (21): 3837.

https://doi.org/10.1182/blood.V124.21.3837.3837

Published: 2014

Journal Articles

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

Avital L. Amir, Dirk M. van der Steen, Renate S. Hagedoorn, Michel G. D. Kester, Cornelis A. M. van Bergen, Jan W. Drijfhout, Arnoud H. de Ru, J. H. Frederik Falkenburg, Peter A. van Veelen, Mirjam H. M. Heemskerk

Blood (2011) 118 (26): 6733–6742.

https://doi.org/10.1182/blood-2011-05-354787

Published: 2011

Journal Articles

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

Pleun Hombrink, MSc, Chopie Hassan, Michel G.D. Kester, Cornelis A.M. van Bergen, J.H.F. Falkenburg, MD, PhD, Peter A. van Veelen, Mirjam H.M. Heemskerk, PhD

Blood (2011) 118 (21): 4038.

https://doi.org/10.1182/blood.V118.21.4038.4038

Published: 2011

Journal Articles

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Annemarie Meenhuis, Peter A. van Veelen, Hans de Looper, Nicole van Boxtel, Iris J. van den Berge, Su M. Sun, Erdogan Taskesen, Patrick Stern, Arnoud H. de Ru, Arjan J. van Adrichem, Jeroen Demmers, Mojca Jongen-Lavrencic, Bob Löwenberg, Ivo P. Touw, Phillip A. Sharp, Stefan J. Erkeland

Blood (2011) 118 (4): 916–925.

https://doi.org/10.1182/blood-2011-02-336487

Published: 2011

Includes: Supplemental data

Journal Articles

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

Maarten L. Zandvliet, J.H. Frederik Falkenburg, Michel G.D. Kester, Arnoud H. de Ru, Peter A. van Veelen, Roelof Willemze, Henk-Jan Guchelaar, Pauline Meij

Blood (2008) 112 (11): 3904.

https://doi.org/10.1182/blood.V112.11.3904.3904

Published: 2008

Journal Articles

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

Cornelis A. M. van Bergen, Michel G. D. Kester, Inge Jedema, Mirjam H. M. Heemskerk, Simone A. P. van Luxemburg-Heijs, Freke M. Kloosterboer, W. A. Erik Marijt, Arnoud H. de Ru, M. Ron Schaafsma, Roel Willemze, Peter A. van Veelen, J. H. Frederik Falkenburg

Blood (2007) 109 (9): 4089–4096.

https://doi.org/10.1182/blood-2006-08-043935

Published: 2007

Journal Articles

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Cornelis A. Van Bergen, Michel G. Kester, Inge Jedema, Mirjam H. Heemskerk, Simone A. Van Luxemburg, Freke M. Kloosterboer, Erik W. Marijt, Arnoud H. De Ru, Martyn R. Schaafsma, Roelof Willemze, Peter A. Van Veelen, J.H. Frederik Falkenburg

Blood (2006) 108 (11): 549.

https://doi.org/10.1182/blood.V108.11.549.549

Published: 2006

NARROW

Expanding the repertoire reveals recurrent, cryptic, and hematopoietic HLA class I minor histocompatibility antigens

T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Immunotherapy Targeting Mutant Nucleophosmin-1 on Acute Myeloid Leukemia

Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain

Immunotherapy By Targeting CD45 in Mismatched HLA-DP to Treat Patients after Allogeneic Stem Cell Transplantation

Permissive HLA-DPB1 mismatches in HCT depend on immunopeptidome divergence and editing by HLA-DM

Mutated NPM1 As Target for Immunotherapy of Acute Myeloid Leukemia

TCR-based therapy for multiple myeloma and other B-cell malignancies targeting intracellular transcription factor BOB1

Endogenous Immunoglobulin-Derived Neoepitopes Are Processed and Form a Sizeable Fraction of the HLA Class I Ligandome of Human Lymphoma Cells

T Cell Receptor Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma and Other B Cell Malignancies

ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation

Therapeutic targeting of the BCR-associated protein CD79b in a TCR-based approach is hampered by aberrant expression of CD79b

T Cell Receptors Specific for the Intracellular Transcription Factor Bob1 Allow Efficient Targeting of Human B Cell Leukemia and Multiple Myeloma

High-Affinity CD20-Specific T-Cell Receptors Suitable for Adoptive Immunotherapy in the Treatment of CD20 low B-Cell Malignancies

Allo-HLA–reactive T cells inducing graft-versus-host disease are single peptide specific

HLA-Peptidomics and the Identification of Clinical Relevant Minor Histocompatibility Antigens,

MiR-17/20/93/106 promote hematopoietic cell expansion by targeting sequestosome 1–regulated pathways in mice

Sequence Dependent Efficiency of Cross-Presentation in MHC Class I Requires Rational Design of Long Synthetic Peptides for Vaccination or Ex Vivo Activation

Multiple myeloma–reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene

ATP Dependent Interferon Responsive (ADIR) Gene Encodes an Activation Induced Minor Histocompatibility Antigen Recognized on Multiple Myeloma by CD8+ T Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only